DIM Stock Overview
Engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Sartorius Stedim Biotech S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €188.10 |
| 52 Week High | €277.90 |
| 52 Week Low | €144.40 |
| Beta | 0.67 |
| 1 Month Change | 11.67% |
| 3 Month Change | 3.92% |
| 1 Year Change | -19.72% |
| 3 Year Change | -59.85% |
| 5 Year Change | n/a |
| Change since IPO | -38.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| DIM | AT Life Sciences | AT Market | |
|---|---|---|---|
| 7D | -2.4% | -0.7% | -1.1% |
| 1Y | -19.7% | -3.9% | -1.6% |
Return vs Industry: DIM underperformed the Austrian Life Sciences industry which returned -3.9% over the past year.
Return vs Market: DIM underperformed the Austrian Market which returned -1.6% over the past year.
Price Volatility
| DIM volatility | |
|---|---|
| DIM Average Weekly Movement | 6.7% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in AT Market | 6.3% |
| 10% least volatile stocks in AT Market | 2.1% |
Stable Share Price: DIM's share price has been volatile over the past 3 months compared to the Austrian market.
Volatility Over Time: DIM's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 10,082 | Rene Faber | www.sartorius.com |
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products.
Sartorius Stedim Biotech S.A. Fundamentals Summary
| DIM fundamental statistics | |
|---|---|
| Market cap | €18.32b |
| Earnings (TTM) | €160.60m |
| Revenue (TTM) | €2.74b |
114.1x
P/E Ratio6.7x
P/S RatioIs DIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIM income statement (TTM) | |
|---|---|
| Revenue | €2.74b |
| Cost of Revenue | €1.55b |
| Gross Profit | €1.19b |
| Other Expenses | €1.02b |
| Earnings | €160.60m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 28, 2025
| Earnings per share (EPS) | 1.65 |
| Gross Margin | 43.33% |
| Net Profit Margin | 5.87% |
| Debt/Equity Ratio | 68.4% |
How did DIM perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield38%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 16:12 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sartorius Stedim Biotech S.A. is covered by 31 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stéphan Dubosq | Arkeon Finance |
| Charles Pitman-King | Barclays |
| Scott Bardo | Berenberg |